Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based regimens combined with tyrosine kinase ...
A safety trial of antibiotic fecal microbiota transplantation for esophageal and gastric cancer patients treated with immune checkpoint inhibitors (Biorich2 trial). This is an ASCO Meeting Abstract ...
Experts discuss the KEYMAKER-U03 trial, highlighting lenvatinib plus belzutifan as a promising option in advanced renal cell carcinoma and new directions emerging from the 2025 American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results